Biotechnology industries

Pharmaceutical industry

Interim Results from Phase I Clinical Trial of ADCETRIS in Combination with Chemotherapy for Newly Diagnosed Advanced Stage Hodgkin Lymphoma Patients

Seattle Genetics and Millennium: The Takeda Oncology Company announced interim results from a phase I clinical trial of ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed advanced stage Hodgkin lymphoma patients. The data were presented at the 53rd American Society of Hematology (ASH) Annual Meeting

Pharmaceutical industry

Updated Data Show Promising Results for ADCETRIS in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company announced updated data from a pivotal trial of single-agent ADCETRIS in relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition in December 2011. The trial showed that 59 percent

Pharmaceutical industry

Regeneron Pharmaceuticals Expands Board of Directors with Renowned Scientist Marc Tessier-Lavigne

Regeneron Pharmaceuticals, Inc. has announced the election of Marc Tessier-Lavigne, Ph.D. to its expanded Board of Directors. Dr. Tessier-Lavigne, current President of The Rockefeller University, brings a wealth of experience in leading drug-discovery programs and a strong track record of scientific innovation. His appointment is seen as a strategic

Pharmaceutical industry

Circuit Split on Class Certification in Securities Class Actions Continues Amid Recent Supreme Court Decisions

As the landscape of securities class actions continues to evolve, a recent decision by the Ninth Circuit in Connecticut Retirement Plans and Trust Funds v. Amgen Inc. has further exacerbated a notable split among the circuit courts regarding the requirements for class certification. This split, which includes differing approaches to

Pharmaceutical industry

FDA Revokes Accelerated Approval of Avastin for Breast Cancer Treatment

The U.S. Food and Drug Administration (FDA) has revoked the accelerated approval of Genentech's cancer drug Avastin for the treatment of metastatic breast cancer, citing concerns over its safety and effectiveness. Despite this decision, Avastin will remain in the market as an approved treatment for certain types

Pharmaceutical industry

Marina Biotech Expands Insulin Patent Portfolio with Chinese Grant

Marina Biotech, Inc., a leading oligonucleotide-based drug discovery and development company, has received a patent grant from the State Intellectual Property Office of the People's Republic of China (PRC) for pharmaceutical formulations of intranasal insulin. This grant, combined with existing patent protection in the European theater, further strengthens

Pharmaceutical industry

Breakthrough in Cancer Research: Small Molecule Identified to Disrupt Autophagy and Boost Treatment Efficacy

Researchers at Harvard Medical School, led by Professor Junying Yuan, have made a groundbreaking discovery in the field of cancer research. A small molecule, named spautin-1, has been identified as a potent inhibitor of autophagy, a complex process that cancer cells use to survive under stress conditions. This breakthrough has

Pharmaceutical industry

MedImmune's Innovative Approach to Biotechnology Sector Strengths

MedImmune attributes its position as an industry leader in the manufacture of monoclonal antibodies and live viral vaccines to its unwavering commitment to the development of new biologics with tremendous potential for patients worldwide. The company's innovative approach to discovery, research optimization, process development, and entrepreneurial spirit have

Pharmaceutical industry

Global Liver Cancer Drugs Market Analysis

The global liver cancer market is a rapidly growing segment, with a projected annual revenue of $1.3 billion by 2015, growing at a CAGR of 14.9% from 2007 to 2015. The market is predominantly driven by the increasing prevalence and incidence of liver cancer, particularly in Asia. Nexavar,

Pharmaceutical industry

Marina Biotech Reports In Vivo Dose-Dependent Efficacy with CRN-Substituted miRNA Antagonist

Marina Biotech, a leading oligonucleotide-based drug discovery and development company, has reported in vivo dose-dependent efficacy with a CRN-substituted miRNA antagonist against microRNA-122 (miR-122). The efficacy was demonstrated in a rodent model by up to a 5-fold increase in AldoA, a downstream gene regulated by miR-122. The increase in downstream

Pharmaceutical industry

Immunoglobulins and Interleukin-6 Mediated Suppression of Hepatic Drug-Metabolizing Enzymes

Researchers from Amgen have published a study in the journal Drug Metabolism and Disposition, examining the effects of interleukin-6 (IL-6) on drug-metabolizing enzymes in human hepatocyte culture. The study found that IL-6 suppresses the activity of 10 major cytochrome P450 isoenzymes, with varying EC(50) values. The study also showed

Pharmaceutical industry

VistaGen Therapeutics Announces Issuance of Two U.S. Patents

VistaGen Therapeutics, a biotechnology company, has announced the issuance of two new U.S. patents, further enhancing its intellectual property portfolio and providing additional protection for its proprietary research and development activities. The patents, U.S. Patent 7,763,466 and U.S. Patent 7,955,849, cover methods for